Clinical Evaluation for Medical Devices — EU MDR Guide for Indian Manufacturers Targeting European Markets (2026) 

Clinical Evaluation for Medical Devices — EU MDR Guide for Indian Manufacturers Targeting European Markets (2026)  

India exported over USD 3.5 billion in medical devices in FY2024–25 — and the European Union is one of the most important destination markets for Indian manufacturers in categories ranging from surgical instruments and orthopaedic implants to diagnostic equipment and single-use devices. But the regulatory barrier to the EU market has become significantly more demanding in the last three years.

Under EU MDR 2017/745, clinical evaluation is the most technically challenging compliance requirement — and the one where Indian manufacturers most frequently encounter Notified Body pushback, Requests for Information (RFIs), and delayed certification. According to MedTech Europe’s 2024 Regulatory Survey, 50% of medical device manufacturers reported that clinical evaluation for at least one MDR application was significantly challenged by their Notified Body.

For Indian manufacturers — many of whom are navigating EU MDR clinical requirements for the first time, or transitioning legacy CE-marked devices from the old MDD directive — this guide explains what clinical evaluation actually requires, where Indian manufacturers specifically struggle, and what a strong clinical evidence strategy looks like in practice.

Why Clinical Evaluation Is the Biggest EU MDR Challenge for Indian Manufacturers  

India’s CDSCO framework under MDR 2017 requires performance testing and safety data — but it does not require the same systematic, lifecycle-based clinical evaluation structure that EU MDR demands. This regulatory gap is the primary reason Indian manufacturers are caught off-guard when Notified Bodies review their EU MDR technical documentation.

The specific gaps that surface most frequently:

• Clinical data compiled but not systematically evaluated — no clinical evaluation plan, no methodology, no PRISMA-standard literature search
• Benefit-risk analysis stated qualitatively (“benefits outweigh risks”) without benchmarking against current standard of care
• PMCF described generically — not specifically linked to device’s evidence gaps
• Equivalence claimed based on general similarity — without demonstrating the technical documentation access that MDCG 2020-5 requires
• CER prepared once for initial certification, never updated — Notified Bodies expect living documents
• Understanding what constitutes sufficient clinical evidence is the biggest challenge to generating an MDR-compliant CER — and there is a recognised knowledge and skills gap in generating acceptable regulatory and clinical data

Over 60% of high-risk device manufacturers have outsourced the writing of their clinical evaluation reports — a figure that reflects both the specialised expertise required and the risk of getting it wrong independently.

EU MDR vs India MDR 2017 — Clinical Evaluation Comparison  

Understanding how the two frameworks differ is the starting point for Indian manufacturers building their EU MDR clinical evidence strategy:

Key insight for Indian manufacturers: The clinical data you collected for CDSCO registration — performance test reports, safety data, pre-clinical studies — is valuable and can contribute to your EU MDR CER. However, it must be systematically evaluated and structured per MDCG 2020-13, and it will almost certainly need to be supplemented with published literature, state-of-the-art analysis, and a formal benefit-risk comparison against alternatives. The raw data is not enough by itself.

What Is Clinical Evaluation Under EU MDR — The Fundamentals  

Under Annex XIV Part A of EU MDR 2017/745 and Article 61, clinical evaluation is defined as “a systematic and planned process to continuously generate, collect and appraise clinical data to verify the safety and performance of a device throughout its lifecycle.”

The four interconnected documents that form the clinical evaluation lifecycle:

1

Clinical Evaluation Plan (CEP)  

Defines your methodology, endpoints, acceptance criteria, and data sources before evaluation begins. Notified Bodies check whether your CER methodology was planned or improvised. Indian manufacturers often skip this — it should be prepared at design stage, not at regulatory submission time.

2

Clinical Data Collection  

From clinical investigations, peer-reviewed literature, equivalent device data, and post-market use. Sources must be systematically identified and quality-assessed — not selectively picked. For Indian manufacturers, this is where your CDSCO performance data, any published clinical studies, and systematic literature review all converge.

3

Clinical Evaluation Report (CER)  

The main document structured per MDCG 2020-13 — evaluating all clinical data and concluding on safety and performance. A living document updated continuously. The CER is not a summary — it is the main clinical defence of your device. Every claim needs traceable proof.

4

Post-Market Clinical Follow-up (PMCF)  

Mandatory ongoing data collection after market entry. The PMCF Plan (MDCG 2020-7) and PMCF Evaluation Report (MDCG 2020-8) feed findings back into each CER update cycle. For Indian manufacturers entering the EU market for the first time, PMCF must be planned and resourced before CE marking — not designed after.

Clinical Evidence Requirements by Device Class — What Indian Manufacturers Need  

The CER Structure Indian Manufacturers Must Follow — MDCG 2020-13  

Every CER submitted for EU MDR must follow the structure defined in MDCG 2020-13. Notified Bodies compare your CER against this document. Here is what each section requires:

Section 1 — Device Description and Intended Purpose  

Precisely defined intended purpose, indications, target population, contraindications, and device variants. If the intended purpose is vague, nothing else in the CER will hold — poorly written claims force weak literature mapping later. Indian manufacturers used to CDSCO’s device master file format need to translate this into EU MDR’s intended purpose statement with greater clinical specificity.

Section 2 — State of the Art (SOTA)  

This is the section most commonly missing or superficial in Indian manufacturers’ CERs. The SOTA must document:

• Current standard of care for your device’s intended indication
• Available alternative treatments and competing devices on the EU market
• Clinical practice guidelines from relevant European medical societies
• How your device’s benefit-risk profile compares against these alternatives

A CER that states “benefits outweigh risks” without benchmarking against the state of the art is insufficient under MDCG 2020-13 — and is a leading cause of Notified Body RFIs.

Section 3 — Clinical Data — Systematic Review  

Clinical data must be collected and quality-assessed systematically — not selectively. For 2026, Notified Bodies increasingly expect a PRISMA flow diagram showing the literature search methodology — search strategy, screening criteria, and inclusion/exclusion decisions. Include this in every literature-based evaluation. Post-market data must now include real-world evidence where available.

Section 4 — Equivalence Data (If Applicable)  

Many Indian manufacturers attempt to use equivalence claims based on general similarity to existing CE-marked devices. Under MDCG 2020-5, this is significantly more demanding than it appears:

• Technical equivalence — same design, materials, specifications
• Biological equivalence — same materials in contact with same tissues
• Clinical equivalence — same intended purpose, indication, patient population

Critically: the manufacturer must have sufficient access to the technical documentation of the equivalent device. If the equivalent device belongs to a competitor and full technical file access is unavailable — equivalence cannot be claimed. In that case, a clinical investigation may be required. Indian manufacturers claiming equivalence to European competitor devices often discover this access barrier too late.

Section 5 — Benefit-Risk Analysis  

Must explicitly:

• Quantify clinical benefit — measurable, patient-relevant outcome measures
• Map every identified risk to the risk management file (ISO 14971)
• Compare benefit-risk ratio against current standard of care
• Map clinical evidence to specific GSPRs (General Safety and Performance Requirements) from Annex I

Evidence depth over breadth — qualitative claims are not sufficient. The justification must include measurable clinical benefit, not just a literature review.

Section 6 — Conclusions and PMCF Linkage  

Every identified gap in clinical evidence must be explicitly linked to a specific PMCF activity. Generic PMCF plans — “we will conduct user surveys annually” — are a Notified Body finding. PMCF activities must address the specific residual risks and evidence gaps of your device.

The Equivalence Challenge — What Indian Manufacturers Face  

Equivalence is the most common clinical evaluation strategy for Indian manufacturers entering the EU — and the one that most often fails under MDR scrutiny. Here is why:

Under the old MDD directive, equivalence was relatively straightforward. Under EU MDR and MDCG 2020-5, the bar is dramatically higher. The practical consequence for Indian manufacturers:

• If your equivalent device is made by a European competitor — you cannot access their full technical documentation. Equivalence fails.
• If your equivalent device is one of your own previously CE-marked products (under MDD) — equivalence may be possible if you have complete technical documentation. But the MDD technical file must still meet MDR clinical evidence standards, not just MDD standards.
• If no substantiated equivalence is possible — a clinical investigation (clinical trial) under MDR Chapter VI may be required before EU market entry. This is a significant time and budget implication that must be planned for from product development stage.

When Indian Manufacturers Need a Clinical Investigation for EU MDR  

For Class III and Class IIb implantable devices, a clinical investigation is required under Article 61(4) unless:

• The device is a modification of an already CE-marked device, OR
• Equivalence to an already CE-marked device can be fully demonstrated per MDCG 2020-5

For Indian manufacturers, this means that novel or innovative devices — even those already CDSCO-registered and selling in India — may require a clinical trial before EU market entry if equivalence cannot be established. Planning implications:

PMCF — Practical Planning for Indian Manufacturers  

PMCF is mandatory under Annex XIV Part B for most device classes — and it must be planned before CE marking, not designed after market entry. For Indian manufacturers, the practical challenge is establishing PMCF infrastructure in the EU market simultaneously with building commercial distribution.

Realistic PMCF options for Indian manufacturers at different scale levels:

2025–2026 EU MDR Clinical Evaluation Updates — What Indian Exporters Must Know  

• Legacy MDD Transition Extended — Regulation (EU) 2024/1860: Transitional provisions for legacy MDD-certified devices extended until 2027–2028 depending on device class. However, this extension applies to Notified Body certificate timelines — not to manufacturers’ obligation to submit MDR-compliant dossiers. Indian manufacturers with MDD legacy certificates must still submit updated technical documentation including MDR-compliant CERs.
• 50% of manufacturers challenged by Notified Bodies (MedTech Europe 2024): This statistic confirms that clinical evaluation quality is the leading cause of MDR delays globally — and Indian manufacturers without dedicated clinical evaluation expertise face higher-than-average risk of NB findings.
• MDCG 2025-6 — AI Act and MDR for SaMD: For Indian manufacturers with AI/ML-enabled diagnostic devices, both EU MDR clinical evaluation and EU AI Act technical documentation requirements now apply simultaneously. Clinical evaluation for AI SaMD must address algorithmic performance as part of the clinical evidence.
• EUDAMED Clinical Investigation Module — Mandatory May 2026: All clinical investigations must be registered in EUDAMED from May 2026. Indian manufacturers planning clinical studies in the EU must plan for EUDAMED registration as part of their study setup process.
• December 2025 European Commission Proposal: Signals additional shifts in MDR clinical data expectations — track this development as it may affect CER requirements for devices seeking certification in 2027 and beyond.

Practical Roadmap: Building Your EU MDR Clinical Evidence Strategy  

Step 1: Classify Your Device Under EU MDR (Not CDSCO)  

EU MDR and India MDR classifications do not map directly. Confirm your EU device class using EU MDR Annex VIII classification rules — or MDCG guidance for borderline products. This determines the entire clinical evidence burden and Notified Body involvement required.

Step 2: Assess Equivalence Realistically  

Identify whether a substantiated equivalence claim is possible under MDCG 2020-5. Be honest about technical documentation access. If equivalence is not viable, factor clinical investigation timeline and cost into your EU market entry plan from day one.

Step 3: Inventory Your Existing Clinical Data  

Audit what you have: CDSCO performance data, pre-clinical studies, published literature, any adverse event or complaint data from India or other markets. Assess each source for quality, relevance, and whether it meets MDR’s clinical evidence standards. This audit defines your evidence gap — which drives your CER content and PMCF plan.

Step 4: Commission a PRISMA-Standard Systematic Literature Review  

For every EU MDR CER, a systematic literature review per PRISMA methodology is now standard Notified Body expectation. This is a significant step up from a general literature search — it requires a documented search strategy, inclusion/exclusion criteria, quality assessment of each paper, and a PRISMA flow diagram. Plan for 4–8 weeks of specialist work.

Step 5: Prepare CER per MDCG 2020-13  

Draft the full CER — CEP, device description, SOTA, clinical data, equivalence (if applicable), benefit-risk analysis, and PMCF linkage — per MDCG 2020-13’s structure. Map each clinical evidence piece to the specific GSPR it supports. Map each evidence gap to a specific PMCF activity.

Step 6: Design Your PMCF Plan Before CE Marking  

Use MDCG 2020-7 as the template. Define specific PMCF objectives tied to your CER’s evidence gaps, the methods you will use (surveys, registry, literature surveillance), timelines, and how results will feed into the next CER update. Submit this alongside your CER — not as an afterthought.

Step 7: Build the CER Update Cycle Into Your Quality System  

Once CE marked, your CER must be updated according to your device class schedule. Build CER update triggers into your QMS — annual for Class III/IIb implants, biennial for IIb non-implantable, upon significant new safety information for all classes. Indian manufacturers often let CERs become stale — this is a surveillance finding risk during Notified Body periodic audits.

The Bottom Line for Indian Manufacturers  

EU MDR clinical evaluation is the most significant technical challenge for Indian manufacturers targeting European markets — and the area where most delays and Notified Body findings occur. The gap between CDSCO’s clinical data requirements and EU MDR’s structured, lifecycle-based clinical evaluation framework is real — but it is manageable with the right strategy, the right expertise, and the right lead time.

Indian manufacturers who invest in building clinical evaluation competence — or partnering with experienced clinical evaluation specialists — will reach the EU market faster, with fewer NB findings, and with stronger long-term CE certificate sustainability than those who treat clinical evaluation as a documentation exercise.

Start your CEP at product development stage. Commission systematic literature review early. Be honest about equivalence. Design PMCF before CE marking. And build the update cycle into your QMS from day one.

Need Help with Clinical Evaluation for EU MDR — India to Europe?  

We assist Indian medical device manufacturers with EU MDR clinical evaluation support — from initial strategy to CER preparation to Notified Body submission:

• EU MDR device classification and equivalence feasibility assessment
• Clinical Evaluation Plan (CEP) development
• PRISMA-standard systematic literature review
• Equivalence assessment per MDCG 2020-5
• Full CER preparation per MDCG 2020-13
• PMCF Plan preparation (MDCG 2020-7 template)
• Notified Body RFI response support
• CER annual update management
• India CDSCO clinical data integration into EU MDR evidence strategy